engleski

Chemotherapy and spleen peptides preparation, SP-1, (Polyerga TM) in the treatment of experimental lung metastases of mammary carcinoma in mice

Aim. To study the influence of chemotherapy with cyclophosphamide and/or spleen peptides" preparation SP-1, PolyergaTM, on the incidence or experimental lung metastases of mammary carcinoma in mice. Method. Mammary carcinoma cells were injected i.v. into CBA/HZgr mice to obtain experimental lung metastases. One day later, a single injection of cyclophosphamide (50 mg/kg) was given i.p., and/or different concentrations of Polyerga were given perorally in drinking water until the end of the experiment. The mice were killed and the number of lung metastatic nodules determined. Results. Peroral application of PolyergaTM was effective in reducing the number of experimental lung metastases. Even the smallest dose (0.05 mg/kg, 100-fold lower than the dose used in human practice) had statistically significant effect (p=0.042). By increasing the dose of PolyergaTM, its effectiveness was more pronounced. The dose of 5.0 mg/kg was as effective as a 100-fold higher dose, and was chosen for further experiments in combination with cyclophosphamide. Mice treated with the combined therapy were without tumor or the number of metastases was significantly reduced (p<0.00l). Conclusion. PolyergaTM preparation is active against tumor metastases, particularly if combined with the standard chemotherapy.

mammary neoplasms ; experimental ; metastasis ; peptides ; therapy

nije evidentirano